Dipyridamole is used for secondary prophylaxis in ischemic stroke and as a vasodilator agent in myocardial scin tigraphy. An important side effect to administering dipyrid amole is headache. The aim of the current study was to inves tigate the effects of dipyridamole on cerebral blood flow, large artery diameter, and headache induction. Twelve healthy sub jects were included in this single-blind placebo-controlled study in which placebo (0.9% NaCI) and dipyridamole 0.142 mg/kg'min were administered intravenously over 4 minutes I hour apart. Blood flow velocity in the middle cerebral artery (V mea> was recorded by transcranial Doppler and regional ce rebral blood tlow in the middle cerebral artery (rCBFrnea) was measured using single photon emission computed tomography and '33Xenon-inhalation. Blood pressure, heart rate, and pC02 were measured repeatedly. Headache response was scored ev-Dipyridamole is used clinically for secondary preven tion in ischemic cerebrovascular disease (Diener, 1998) . Intravenous administration of dipyridamole combined with thallium-20l myocardial perfusion imaging is also used as a nonexercise cardiac stress test in patients un able to perform a physical stress test (Laarman et aI., 1988).
Summary: Dipyridamole is used for secondary prophylaxis in ischemic stroke and as a vasodilator agent in myocardial scin tigraphy. An important side effect to administering dipyrid amole is headache. The aim of the current study was to inves tigate the effects of dipyridamole on cerebral blood flow, large artery diameter, and headache induction. Twelve healthy sub jects were included in this single-blind placebo-controlled study in which placebo (0.9% NaCI) and dipyridamole 0.142 mg/kg'min were administered intravenously over 4 minutes I hour apart. Blood flow velocity in the middle cerebral artery (V mea> was recorded by transcranial Doppler and regional ce rebral blood tlow in the middle cerebral artery (rCBFrnea) was measured using single photon emission computed tomography and '33Xenon-inhalation. Blood pressure, heart rate, and pC02 were measured repeatedly. Headache response was scored ev-Dipyridamole is used clinically for secondary preven tion in ischemic cerebrovascular disease (Diener, 1998) . Intravenous administration of dipyridamole combined with thallium-20l myocardial perfusion imaging is also used as a nonexercise cardiac stress test in patients un able to perform a physical stress test (Laarman et aI., 1988) .
Dipyridamole has two main mechanisms of action: inhibition of adenosine reuptake increasing the circulat ing level of adenosine and inhibition of phosphodiester ases (PDEs) leading to an increase in cyclic guanosine monophosphate (cGMP) and cyclic adenosine mono phosphate (cAMP) (FitzGerald, 1987; Sakuma et aI., ery 10 minutes on a verbal scale from a to 10 (10 = worst).
Dipyridamole caused a decrease in pC02 (P < 0.001). pC02 corrected rCBFmea was 41.7 ± 6.9 mLiIOO g 'min after placebo versus 41.2 ± 6.9 after dipyridamole (P 2: 0.05). pCOz cor rected Vmea decreased 8.4% ± 11.7 (P < 0.001) after dipyrid amole, indicating a mean 5.6% ± 6.7 (P = 0.005) relative increase of the arterial diameter. After dipyridamole the median peak headache score was 2 (range a to 7) compared with a (range a to 3) after placebo (P = 0.02). Dilatation of the middle cerebral artery outlasted the headache response. In con clusion, dipyridamole causes a modest pCOz independent di latation of the MCA, which is time-linked to the onset, but not to the cessation, of headache. Key Words: Dipyridamole Cerebral blood f1ow-Vasodilatation-Phosphodiesterase in hibitor-Headache. 1990). Dipyridamole has been reported to have effects on the cerebral circulation in animals, but its effect on the cerebral circulation in humans has not been fully elucidated.
The most common side effect of dipyridamole both after oral and intravenous administration is headache, which has been reported in 37% of subjects after oral administration and 25% of subjects after intravenous in fusion (Diener, 1998; Laarman et aI., 1988) . This head ache inducing ability of dipyridamole has not been de scribed systematically in a prospective study, and the exact characteristics of the headache and its possible mechanisms have not been evaluated. Previous experi mental studies have shown that nitric oxide (NO) releas ing compounds, or NO donors, capable of inducing head ache, also dilate large cerebral arteries without a con comitant change in cerebral blood flow (Dahl et aI., 1989; Lassen et aI., 1995; Thomsen et aI., 1993) . Nitric oxide causes a rise in cGMP in the vascular smooth muscle cell. An increase in cGMP can also be achieved by inhibition of cGMP hydrolyzing PDEs through com pounds like dipyridamole. The aim of the current study was to examine the effects of dipyridamole on regional cerebral blood flow (rCBF) in the middle cerebral artery territory (rCBF mea ) by 133 -Xenon single photon emission computed tomography (SPECT) and the effects on mean blood flow velocity in the middle cerebral artery (V mea ) ' and furthermore, to quantify, characterize, and time any headache caused by dipyridamole, and relate it to the observed hemodynamic changes. Such a study may not only elucidate the mechanisms of dipyridamole-induced headache, but it may also contribute toward understand ing the mechanisms of vascular headache in general.
MATERIALS AND METHODS

Desi g n and material
The current study was a single-blind placebo-controlled study in which placebo (0.9% NaCI) was administered intra venously over 4 minutes. On the same day, I hour after placebo infusion, dipyridamole 0.142 mg/kg'min was administered in travenously for 4 minutes.
The subjects were blinded to the order of treatments. In addition, the investigators analyzing the CBF data were also blinded to the design of the study and were unaware of the order of infusions. Preliminary studies had shown that the ef fect of dipyridamole on blood flow velocity lasted more than I hour, therefore the order of infusions was the same for each subject to avoid a carry-over effect of dipyridamole. The study was performed using intravenous administration of dipyrid amole to avoid possible variation in bioavailability (FitzGerald. 1987) . A dose similar to the dose used for routine cardiovas cular performance tests was chosen for the study.
Twelve healthy subjects. seven women and five men. were included (age range 18 to SO years, mean = 30.1 years). The subjects had no medical history of cerebrovascular or cardio vascular disorders. migraine, hypo-or hypertension, and had a headache frequency of less than 2 days a month. All subjects gave written informed consent before inclusion and a medical examination, including an ECG, was performed before the study. The study was approved by the ethical committee of Copenhagen County and the Danish health authorities and was conducted according to the Helsinki II declaration.
Headache recordin g s
During the study, headache intensity was scored every 10 minutes on a verbal scale from 0 to 10, where I represents a very mild headache (including a feeling of pressing or throb bing), 5 a headache of moderate intensity, and 10 the worst headache imaginable (Iversen et aI., 1989) . Also, headache characteristics, headache location, and other side effects were recorded. All subjects were asked to record their headache, headache characteristics, and any intake of medication every hour at home on a headache diary card from 2 to 10 hours after the dipyridamole infusion. The subjects were allowed to treat their headache at home with plain analgesics. Time for intake and drugs used were recorded in the headache diary card.
Blood flow velocity
A time-averaged mean of the maximal blood velocities in the middle cerebral artery (V mca) was recorded bilaterally by trans cranial Doppler (2 MHz, Multidop X Doppler, DWL; Liibech & Sipplingen, Sipplingen, Germany) using handheld probes (Thomsen et aI., 1993) . The average of 4 measurements com prising approximately 4 cardiac cycles each over a time interval of 30 seconds was used. A fixed point for measurements of V mea was chosen along the MCA as the point that was as close as possible to the bifurcation between the MCA and the anterior cerebral artery. This fixed point was then used throughout the study in each subject, and every measurement was done after carefully optimizing the signal from this point. Measurements of pC02 were performed simultaneously with the transcranial Doppler measurements (POET; Criticare Systems, Waukesha, WI, U.S.A.) using a mask placed lightly over the nose and mouth.
Cerebral blood flow measurements
Measurements of CBF were performed with 133_Xenon in halation and SPECT using a brain-dedicated camera, Ceraspect (DSI, Waltham, MA, U.S.A.), with a stationary annular NaI crystal and a fast rotating collimator system. Each rotation took 10 seconds, acquiring I frame in a 30-frame dynamic profocol of 133Xenon-inhalation (3 background, 9 wash-in, 18 wash-out) using the Kanno-Lassen algorithm (Kanno and Lassen, 1979) . Thirty-two slices were reconstructed in a 64 x 64 matrix with each pixel measuring 0.33 x 0.33 cm. A set of 8 transaxial slices was generated by adding 4 slices together to a total slice thickness of 1.33 cm. Attenuation correction using the Chang algorithm (fL = 0.05 cm) and nose-artefact correction was performed. The output in each pixel was the kl value. The kl was corrected with a partition coefficient (A) = 0.85 mUg to get CBF values (mUIOO g·min).
A Datex Normocap 200 (Dameca, Rfdovre, Denmark) was used for end-tidal CO2 measurements during CBF acquisition. A Xenamatic 4000 (Diversified Diagnostic Products, Houston, Texas, U.S.A.) was used for I 33Xenon-administration. The measurement lasted 5 minutes. A standard vascular region of interest set of 5 slices positioned 3.6, 5.0, 6.3, 7.6, and 9.0 cm above the cantho-meatal plane was used.
Because transcranial Doppler was performed on the MCA, the distribution area for the MCA was chosen as a region of interest for further analysis. Mean blood flow in the perfusion area of MCA for each side was calculated, and a mean of left and right rCBFmea values was analyzed. Global CBF was cal culated as an average of all regions of interest.
Procedures
The subjects arrived without headaches at 8:30 in the morn ing on the day of the study. No medication, coffee, tea, alcohol, tobacco, or chocolate were allowed for at least 8 hours before start of the examination. After a short medical examination, including an ECG, a cannula was inserted in the cubital vein for infusion of placebo and dipyridamole. The subjects were kept in supine position during the study. After 30 minutes rest, base line measurements of blood pressure, heart rate, pC02, V mea' and CBF were performed. To avoid accumulation of radioac tivity, causing high background readings during CBF measure ments, a 40-minute interval was included between baseline CBF measurement and the next CBF measurement, which was performed immediately after a 4-minute placebo infusion. Sixty minutes after start of the placebo infusion, dipyridamole was infused and a third CBF measurement was performed at the end of infusion. After another interval of I hour, the final CBF measurement was performed. Vmca was recorded every 20 min utes from SO minutes before infusion of placebo to end of the final CBF measurement. In connection with the CBF measure ments, the Vmca measurements were performed immediately at the end of each CBF measurement. Headache and headache characteristics were scored every 20 minutes from start of pla cebo infusion.
Blood pressure and heart rate were measured repeatedly ev ery 5 minutes using an automatically int1ated arm-cuff. Elec trocardiogram was recorded every 10 minutes during the study.
The estimated perfusion area (rCBFx) of a given artery (x) in the brain depends on the mean blood flow velocity (V x) and the cross-sectional area 1T(r 2 ) of the artery (Dahl et a!., 1989; Sorte berg, 1992) . Based on this assumption an estimate of the rela tive change in the cross-sectional area of the large artery can be made when rCBF x and V x is known. When the cerebral blood flow is unchanged the following equation is valid (Dahl et aI., 1989) :
tl diameter is the relative percentage change in diameter, Vmcal is the blood flow velocity in the MCA before infusion of drugs, and V mca2 is the velocity at a relevant time point after infusion of the drug.
To circumvent the influence of the difference in pC02 over time, and because the mcasurements were not done simulta neously, rCBFmea and V mea were corrected for pC02 changes from baseline. Cerebral blood flow and rCBFmea were cor rected by 2% per mm Hg change in pC02 (Shirahata et aI., 1985) and V mea with an exponential factor of 0.034 mm Hg (Markwalder et aI., 1984) .
Statistics
Statistical analyses were performed on absolute values. Val ues are presented as means ± SD, with headache values as median and (range). P < 0.05 was considered significant.
Changes over time for each variable�Vmct" CBF, rCBFmea, calculated relative artery diameter change, blood pressure, heart rate, and pC02�were analyzed with two-way analysis of variance (Statgraphics 3.3; Manugistics, Rockville, MD, U.S.A.) with factors time and subjects. The two-way analysis of variance was repeated for each single variable. If an overall effect of time was found, further analysis was performed using a multiple range test for location of significant changes (Stat graphics 3.3). Mean values were evaluated according to three time periods: baseline, after placebo, and after dipyridamole. These mean values, together with peak values and the calcu lated area under the curve for the two latter periods, were chosen as summary measures when analyzing difference in response between treatments. The calculated values were com pared using a paired t-test (Statgraphics 3.3). Difference in headache response after placebo and dipyridamole (area under the curve and peak response) were analyzed using Wilcoxon Rank Sum Test (SPSS 9.0). 
RESULTS
End-expiratory pC02 decreased significantly (P < 0.00 I) over time after dipyridamole infusion compared with baseline, returning to baseline 40 minutes after in fusion (Fig. 1) . The mean and peak end expiratory pC02 after dipyridamole was significantly different from that seen after placebo (P < 0.003; Table 1 ). Peak decrease in pC02 from baseline was 0.4% ± 3.5 after placebo and 5. 6% ± 3. 3 after dipyridamole.
Mean rCBFmca was 41.2 ± 7.0 mLiIOO g·min at base line and global CBF was 42.0 ± 7.l. There was no sig nificant change over time compared with baseliHe in rCBFmca (P = 0. 26) or global CBF (P = 0.24) when values were corrected for the change in pC02 induced by dipyridamole. Mean rCBFmca was 42.7 ± 7.4 mLiIOO g·min after placebo versus 42.3 ± 7.6 after dipyridamole (P = 0.67). Corresponding values for global CBF was 43.3 ± 7. 5 mLiIOO g·min and 42.4 ± 7. 5 mLilOO g·min (P = 0.40) for placebo and dipyridamole, respectively.
When no pC02 correction was performed, a signifi cant decrease from baseline in rCBFmca (P = 0.02) and global CBF (P = 0.01) was seen immediately after di pyridamole infusion, with values returning to baseline I hour after dipyridamole infusion. Without pC02 correc tion, rCBFmca values after placebo were 42.7 ± 6.6 mLi 100 g·min and after dipyridamole were 39.6 ± 6.7 mLi 100 g /min (P = 0.009), and global CBF was 43.3 ± 6.7 after placebo and 39.8 ± 6.6 after dipyridamole (P = 0.0(5).
At baseline, mean Vmca was 75.5 ± 13.4 cm/second. Vmca decreased significantly after start of dipyridamole infusion and remained decreased until at least I hour after end of infusion (P < 0.( 1). This was seen both with and without correction for change in pC02 (Fig. I) mean Y m c a in the period after placebo infusion was 74.0 ± 14.7 cm/second and in the period after dipyridamole was 69.2 ± ] 4.6 em/second (P < 0.00 I). This was equal to a mean decrease in velocity from baseline of 8.4% ± 11.7% after dipyridamole (P < 0.00 1) and 1. 6% ± 13.2% after placebo (P = 0 . 3). Thus, compared with placebo mean and peak, values of Y m c a were significantly de creased after dipyridamole (absolute values are shown in Table 1 ). Also, the calculated area under the curves was significantly decreased after dipyridamole (P = 0.00 I).
Using the peo2 corrected values of Y m c a (Dahl et aI., 1989) , the estimated mean relative dilatation from base line was 1. 6% ± 6.7% after placebo and 5. 6% ± 6.7% after dipyridamole (P = 0.005); both mean and peak relative dilatation (P = 0.0 I) was significantly increased after dipyridamole compared with placebo ( Table I) .
Diastolic and systolic blood pressures were unchanged over time (P = 0. 11 and P = 0. 1, respectively). In contrast, heart rate increased 43.6% ± 24.7% immedi ately after infusion of dipyridamole (P < 0.(0 1) com pared with baseline ( Fig. 2) . Mean and peak heart rate was significantly increased (P < 0.001) after dipyrid amole compared with placebo, whereas systolic and di astolic blood pressure showed no significant difference (P 2:-0.05; Table I ).
The area under the headache curve during the first 60 minutes postinfusion was significantly increased after di pyridamole compared with placebo (P = 0.0 1). Of 12 subjects, 4 reported a mild headache after placebo and 8 reported mild to severe headache after dipyridamole with peak intensity 10 to 20 minutes after infusion (Fig. 3) . The median peak headache score after placebo was 0 (range 0 to 3), and the score after dipyridamole was 2 (range 0 to 7, P = 0.02). A second delayed peak in headache scores, exceeding the headache scores imme diately after dipyridamole infusion, was reported in 3 subjects with peak intensity at a mean of 3 hours (range 2 to 5 hours) after dipyridamole infusion. A further 2 subjects reported a similar second headache peak, how ever with a lower headache score than reported after dipyridamole infusion, also occurring 3 hours (range 2 to 4 hours) after dipyridamole infusion. The headache was bilateral and of pressing quality in 7 subjects and unilateral in 1 subject who also experi enced throbbing pain and nausea. This subject fulfilled the criteria for migraine according to the International Headache Society classification (Headache Classifica tion Committee, 1988), but only at one time-point 20 minutes after dipyridamole, migraine symptoms remitted without therapy; the subject had no family history of migraine. The remaining 7 subjects did not fulfil the migraine criteria at any time-point. Two of the subjects experiencing headache took rescue medication (plain an algesics) at home.
Of other side effects recorded, 11 out of 12 subjects showed objective flushing in the face after dipyridamole and only 1 experienced this after placebo. Eight subjects reported a feeling of warmth, 6 subjects experienced pal pitations, and 6 subjects reported a feeling of heaviness in the body after dipyridamole. Electrocardiogram showed no signs of ischemia or arrhythmia during dipy ridamole infusion. After placebo only 2 subjects reported palpitations, I subject reported a feeling of warmth, and 1 subject complained of nausea.
DISCUSSION
Dipyridamole and cerebrovascular hemodynamics
In the current study, global CBF and regional CBF in the middle cerebral artery territory (rCBF mea ) decreased during dipyridamole infusion simultaneous to a decrease in end-expiratory pC02. Previously, Ito et aI. (1999) also observed a decrease in CBF and in pC02 during dipy ridamole infusion. As in the current study, the CBF de crease was thought to be because of hyperventilation attributed to adenosine reuptake inhibition, because adenosine stimulates pulmonary chemoreceptors. There fore, the authors chose to correct V mea, CBF, and rCBF mea for pC02 changes. After correction dipyrid amole had no effect on CBF or rCBF mea' whereas V m ea was still significantly decreased. This suggests dilatation of large conductance arteries. Previous studies have revealed species differences of dipyridamole in the induced CBF response (Heistad et aI., 198 1) . Thus, dipyridamole caused a 2. 7 -fold increase in CBF in rabbits, whereas no increase in CBF was found in cats and dogs (Heistad et aI., 198 1) . Another study on dogs reported no change in CBF, but did report a de creased cerebral vascular resistance after dipyridamole. It was unclear whether this was a direct effect of dipy ridamole on the cerebral resistance vessels or was be cause of autoregulatory dilatation secondary to a 20% decrease in blood pressure (Boarini et aI., 1982) . An increase in CBF was correlated to the plasma levels of cAMP but not to adenosine levels (Hegedus et aI., 1997) .
Topical application of very high concentrations (10 to 100 f,LmoIlL) of dipyridamole dilates pial arterioles in rabbits (Heistad et aI., 198 1) . Likewise, when adminis tered intravenously, only concentrations greater than or equal to 0.7 mg/kg induced a significant increase in CBF (Hegedus et aI., 1997) . This dose far exceeds the doses that can be administered to humans. Thus, there are quite marked species differences in the cerebrovascular re sponse to dipyridamole, which make human studies essential.
Based on the pC02 corrected values showing a de crease in V mea and an unchanged rCBF mea' a significant relative increase in the diameter of the MCA of 5.6% ± 6.7% was calculated. End-expiratory pC02 returned to normal 40 minutes after dipyridamole, whereas V mea re mained significantly decreased until the end of the study and also during the last CBF measurement, which had returned to baseline. This indicates that the change in V mea was caused by the drug and not by hyperventila tion. Allowing for some species difference, the current findings of large artery dilatation and of no direct effect on CBF are largely compatible with previous findings in vitro and in vivo.
The effect of drugs on CBF are not always similar to their effects on large cerebral arteries (Dahl et aI., 1989; Friberg et aI., 199 1) . As demonstrated in the current study and in previous studies, these effects can be dis tinguished by combining quantitative CBF measurement and blood flow velocity measurement (Sorteberg, 1992) . Using 133 -Xenon inhalation rCBF measurement and a brain dedicated SPECT scanner provides reliable quan tified rCBF measurements, although the spatial resolu tion is rather poor (Lassen, 1985) . The latter is not a problem when evaluating drugs for their vasoreactivity, which in all likelihood is similar within each brain re gion. 133 -Xenon SPECT involves only minor radiation exposure and therefore allows several repeated measure ments, a requirement in pharmacologic studies. Trans cranial Doppler is easy to handle, has a good reproduc ibility, and is without known risks for the patients .
Mechanism of action
Pharmacokinetic studies of dipyridamole have re vealed a tri-exponential decrease in plasma concentration over time, the first two steep decreases occurring within 4 to 6 hours after intravenous dipyridamole and the ter minal half-life being approximately 12 hours (Bjornsson and Mahony, 1983; Sollevi, 1986) . The half-life of the effects described below is not known in detail.
Two main mechanisms of action of dipyridamole on the vascular system have been proposed. First, it acts as an inhibitor of adenosine reuptake, increasing the extra cellular level of adenosine. Adenosine in turn activates adenylate cyclase and causes a rise in cAMP. Secondly, dipyridamole inhibits phosphodiesterases (PDEs), pri marily the cGMP-specific PDE5, thereby increasing in tracellular cGMP (Beavo, 1995; FitzGerald, 1987) . PDE5 is present in vascular smooth muscle and platelets (Beavo, 1995) . Both oral administration and intravenous infusion result in levels of dipyridamole in humans that affect both mechanisms (Bjornsson and Mahony, 1983; FitzGerald, 1987) .
Adenosine and cGMP elevating compounds have been shown to induce dilatation of human cerebral arteries (Dahl et aI., 1989; Sollevi, 1986) . Adenosine increases CBF in rabbits but causes no change in the CBF of dogs and cats (Heistad et aI., 198 1) . Zaprinast, a selective PDE5 inhibitor increasing cGMP levels, did not change CBF or cerebral oxygen consumption in rats when it was applied topically (Wei et aI., 1996) , but did dilate guinea pig and human cerebral arteries in vitro (Kruuse et al., unpublished results) .
A consensus has not been reached as to which effect of dipyridamole is the most important, and diverging results and theories have been put forward, especially concern ing the antiaggregatory effect (FitzGerald, 1987; Muller et aI., 1990; Sakuma et aI., 1990) . Adenosine and cAMP have been reported to be increased in plasma after dipy ridamole (Hegedus et aI., 1997; Sollevi, 1986) . A rise in tissue levels of cGMP has also been shown in vitro after dipyridamole administration (Sakuma et aI., 1990) . Fur thermore, dipyridamole enhances the effects of endog enous NO on platelet aggregation (Bult et aI., 1991; Sa kuma et aL 1990) and enhances the effect of inhaled NO on airway smooth muscle (Ziegler et aI., 1998) . Unfor tunately, neither in CBF studies nor platelet studies have cAMP and cGMP after dipyridamole been consistently and simultaneously measured. At present, it can not be determined whether the dilatory effect of dipyridamole on the large cerebral arteries was because of inhibition of adenosine reuptake, POE inhibition and a rise in cGMP, or the combined effect of both mechanisms.
Dipyridamole-induced headache
Migraine and vascular headache may be related to dilatation of cerebral and extracranial arteries (Friberg et aI., 199 1; Thomsen et aI., 1995) . However, vasodilata tion alone seems to be too simplistic of an explanation and no universal agreement exists on this (Thomsen et aI., 1995; Zwetsloot et aI., 1993) . The NO donor Glyc eryl-trinitrate (GTN) and 5-isosorbid mononitrate (5-ISMN) can induce headaches in healthy volunteers and migraines in migraine patients concomitant to dilatation of cerebral and extracranial arteries while CBF remains unaltered (Dahl et aI., 1989; Olesen et aI., 1993) . Similar findings have been made with histamine that stimulates endogenous production of NO through HI receptors on the endothelial cells (Lassen et aI., 1995) . Nitric oxide induces an increase in cGMP through activation of the enzyme soluble guanylate cyclase. This eventually leads to smooth muscle cell relaxation and arterial dilatation. Some doubt has been raised whether headache is induced by stimulation of perivascular pain-sensitive nerve-fibers because of the arterial dilatation, or if NO diffuses through the smooth muscle cells and stimulates the pain sensitive nerve-fibers directly (Thomsen et aI., 1995) .
Dipyridamole induces headache after oral and intrave nous administration, but only the frequency and not the headache intensity, characteristics, or timing have been reported (Diener, 1998; Laarman et aI., 1988 ). In the current study, 8 out of 12 subjects (67%) reported head ache. Previously, in studies that did not focus on head ache, the frequency of headache after intravenous admin istration was reported to be between 8% and 25% (Laar man et aI., 1988) . Headache occurred in 37.2% of stroke patients after administration of 2 x 75 mg slow release tablet daily (Diener, 1998) , and 11 out of 12 healthy subjects reported headache after 200 mg oral dose twice daily (Bult et aI., 199 1) . The variation in reported headache may be because of difference in doses of di pyridamole, age-related difference in cerebrovascular response, or the lack of a systematic registration of this side effect.
In the current study, the authors selected a single blind design to minimize the radiation exposure. Furthermore, the color of dipyridamole used for intravenous infusion (bright yellow) and the side effects of facial flushing were difficult to disguise for the investigator and made it impossible to double blind the study properly. The non randomized order of drug administration chosen reflects the limitations of studies including human subjects. The chosen design may be a confounding factor, which should be kept in mind when interpreting the results of the current study. However, because of the objective measurements used, the single blind design seems un likely to have biased the hemodynamic results. The re ports of delayed headache at the end of the study may have been partially biased by the subjects' knowledge of active treatment. Thus, less emphasis should be placed on these data in the interpretations of the effects of di pyridamole.
The decrease of blood flow velocity in the MCA of 8.4% in the current study is smaller than the 28% seen with GTN (0.5 f..L g/kg·min) (Thomsen et aI., 1993) . How ever, it is in the same range as seen during spontaneous migraine attacks (Thomsen et aI., 1995) . The onset of dipyridamole-induced arterial dilatation is time-wise cor related to the induced headache. Compared with head ache induced by GTN, dipyridamole-induced headache started later, reached its peak more slowly, and lasted longer, which corresponds to the longer half-life of di pyridamole (Iversen et aI., 1989; Olesen et aI., 1993) .
Although headache initiation after dipyridamole cor responded to the decrease in Y m c a ' headache intensity decreased before vasodilatation had diminished. Thus, arterial dilatation may mechanically activate perivascular pain sensitive nerves, but either the algogenic effect of vasodilatation is transient or endogenous antinociceptive mechanisms become temporarily activated to counteract the nociceptive input.
A delayed headache, defined as a second peak of headache, occurred several hours after dipyridamole in fusion. The occurrence of delayed headache has also been reported after GTN in migraine patients and more rarely in healthy subjects (Iversen et aI., 1989) . In pre vious studies of GTN induced headache in normal sub jects, delayed headache occasionally fulfilled the Inter national Headache Society criteria for migraine without aura (Olesen et aI., 1993) and this was seen in one subject in the current study.
A possible mechanism of the delayed headache may be a release of neurotransmitters such as calcitonin gene related peptide, substance P, and NO during vasodilata tion. The release may sensitize the perivascular nerve fibers. Also, the initial volley of nociceptive impulses may sensitize central pain pathways. If one or both of J Cereb Blood Flow Metab. Vol. 20. No. 9, 2000 these mechanisms becomes sufficiently activated, even normal pulsation in the artery may be perceived as pain ful. At the molecular level these effects may be related to the rise in cGMP caused by PDE5 inhibition because other headache-inducing compounds, such as GTN and histamine, are vasoactive and work through the NO cGMP pathway. Understanding these mechanisms in fur ther detail will not only shed light on dipyridamole induced headache and cerebral artery dilatation, thereby offering possibilities of preventing the side effects re lated to the therapeutic use of this agent, but also will add useful information to the understanding of basic head ache mechanisms.
